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Rapamycin Suppresses Self-Renewal and
Vasculogenic Potential of Stem Cells Isolated
from Infantile Hemangioma
Shoshana Greenberger1,4, Siming Yuan1,5, Logan A. Walsh1,6, Elisa Boscolo1, Kyu-Tae Kang1,
Benjamin Matthews1,2, John B. Mulliken3 and Joyce Bischoff1
Infantile hemangioma (IH) is a common childhood vascular tumor. Although benign, some hemangiomas cause
deformation and destruction of features or endanger life. The current treatments, corticosteroid or propranolol,
are administered for several months and can have adverse effects on the infant. We designed a high-throughput
screen to identify the Food and Drug Administration-approved drugs that could be used to treat this tumor.
Rapamycin, an mTOR (mammalian target of Rapamycin) inhibitor, was identified, based on its ability to inhibit
proliferation of a hemangioma-derived stem cell population, human vasculogenic cells, which we had
previously discovered. In vitro and in vivo studies show that Rapamycin reduces the self-renewal capacity of the
hemangioma stem cells, diminishes differentiation potential, and inhibits the vasculogenic activity of these cells
in vivo. Longitudinal in vivo imaging of blood flow through vessels formed with hemangioma stem cells shows
that Rapamycin also leads to regression of hemangioma blood vessels, consistent with its known anti-
angiogenic activity. Finally, we demonstrate that Rapamycin-induced loss of stemness can work in concert with
corticosteroid, the current standard therapy for problematic hemangioma, to block hemangioma formation
in vivo. Our studies reveal that Rapamycin targets the self-renewal and vascular differentiation potential in
patient-derived hemangioma stem cells, and suggests a novel therapeutic strategy to prevent formation of this
disfiguring and endangering childhood tumor.
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INTRODUCTION
Infantile hemangioma (IH) is a common childhood tumor
composed of disorganized blood vessels and immature cells
(Mulliken, 1988; Drolet et al., 1999). It represents a
disruption of neonatal vasculogenesis, the de novo formation
of vessels from progenitor cells, and of angiogenesis, the
sprouting of new vessels from preexisting vasculature. Herein
we show that Rapamycin, an inhibitor of the mammalian
target of Rapamycin (mTOR) pathway, diminishes the self-
renewal capacity of IH-derived stem cells (HemSCs), initiates
the differentiation of HemSCs toward a perivascular cell
phenotype, and inhibits de novo formation of vessels from
HemSCs. This anti-vasculogenic activity of Rapamycin,
which is distinct from its known anti-angiogenic effects, is a
novel discovery, with implications for the mTOR pathway in
human neonatal vasculogenesis, as well as for potentially
new strategies to treat the most endangering IH.
Although a benign and usually harmless tumor, some IH
deform or destroy facial features and/or obstruct vision and
breathing. Approximately 40–80% result in permanent cuta-
neous residua, which can be disfiguring. Corticosteroids are
traditional first-line therapy; however, the adverse effects are
numerous (Boon et al., 1999) and approximately 16% of
hemangiomas do not respond (Bennett et al., 2001). Propra-
nolol has recently been introduced as a safe and effective
treatment for IH (Leaute-Labreze et al., 2008; Siegfried et al.,
2008). However, its use is not without risks, and not all tumors
respond (Frieden and Drolet, 2009). Thus, there is a need for
additional therapies that will shorten the treatment duration or,
ultimately, prevent problematic hemangiomas from forming.
We recently isolated stem cells (HemSCs) and endothelial
cells (HemECs) from specimens of proliferating IH (Boye
et al., 2001; Khan et al., 2008). HemSCs have a mesenchymal
morphology, robust proliferation, undergo multi-lineage
differentiation, and form human blood vessels with features
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of IH when injected subcutaneously into nude mice (Khan
et al., 2008). Corticosteroids inhibit this vessel formation by
suppressing vascular endothelial growth factor (VEGF)-A in
HemSCs, while having no effect on HemECs or normal
human cord blood-derived endothelial progenitor cells
(cbEPCs; Greenberger et al., 2010). However, corticosteroids
have no effect on the proliferation of HemSCs. Therefore, we
hypothesized that a drug that inhibits proliferation of HemSCs
might prevent the growth of proliferating IH. To pursue this,
we screened chemical libraries to identify drugs that
preferentially inhibit the proliferation of HemSCs.
RESULTS
A cell-based screen identifies compounds that selectively inhibit
proliferation of HemSCs
We designed a proliferation assay to test in parallel HemSCs
and bone marrow-derived stem cells (BM-MSCs). BM-MSCs
share several characteristics with HemSCs: expression of
mesenchymal markers, spindle-shaped morphology, and the
potential to differentiate into bone, fat, and cartilage. In
contrast to HemSCs, BM-MSCs do not form vessels when
injected as a single cell type in Matrigel into nude mice (Khan
et al., 2008). The methods and results of the screen are
provided in the Supplementary material (Supplementary
Figure S1, Supplementary Table S1 online).
Of the nine compounds identified, we selected Rapamycin
for further study because its activity was maintained at low
concentrations and its favorable safety profile has been
established in pediatric clinical trials (Sindhi et al., 2005).
Rapamycin led to B40% inhibition of HemSC proliferation
at concentrations of 1 ngml1 and higher, whereas BM-MSCs
or normal human dermal fibroblasts were less sensitive
(Figure 1a). Proliferating cell nuclear antigen served as
an additional measure of proliferation (Prelich et al., 1987;
Hall and Levison, 1990). Rapamycin led to a dose-depen-
dent decrease in the percentage of proliferating cell
nuclear antigen-positive HemSCs, with 80% suppression
at 10 ngml1 (Figure 1b). Viability was not affected by
Rapamycin, as seen by normal cell morphology visualized by
phalloidin staining (Supplementary Figure S2 online).
Rapamycin is an inhibitor of mTOR. To verify that
rapamycin inhibited mTOR in the HemSCs, we tested the
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Figure 1. Rapamycin selectively inhibits the proliferation of HemSCs. (a) Dose–response curves of infantile hemangioma (IH)-derived stem cells (HemSCs; ),
normal human dermal fibroblasts (NHDFs; ), and bone marrow-derived stem cells (BM-MSCs; K) treated with Rapamycin. Error bars denote SD (N¼32).
(b) Quantification of proliferating cell nuclear antigen-positive cells in HemSCs treated with Rapamycin. Error bars denote SD (N¼ 8). *Po0.05 compared
with the nontreated group. (c) Western blot for phospho4EBP-1(S65) and total 4EBP-1 in HemSCs serum-starved for 24 h, pretreated with vehicle alone (‘‘0’’) or
Rapamycin for 20min, and then stimulated with media containing serum and growth factors for 30min. (d) Bands in c quantified using ImageJ; normalized
to b-actin. (e) Immunostaining for phosphorylated AKT (green) and VE-cadherin (red), and staining for 4’,6-diamidino-2-phenylindole (blue), in proliferating
or involuting IH. Scale bar¼50 mm.
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phosphorylation status of two targets of mTOR signaling—
serine/threonine kinase p70 S6 kinase and eIF-4EBP1 (Hara
et al., 1997). Rapamycin caused a dose-dependent decrease
in the constitutive and serum/growth factor-stimulated levels
of phosphorylated 4EBP1 (Figure 1c and d). To verify that
mTOR is a relevant target in IH, we analyzed its upstream
regulator AKT. Phosphorylated AKT was detected in prolif-
erating IH tumor specimens. In contrast, very low expression
was observed in involuting IH specimens (Figure 1e).
Rapamycin suppresses vasculogenesis in the IH tumor model
Next, we tested the effect of systemic Rapamycin in a two-
cell model of IH we reported previously (Greenberger et al.,
2010). HemSCs and cbEPCs were mixed with Matrigel and
injected subcutaneously in nude mice. This two-cell model
has advantages over injecting HemSCs alone: first, it is more
robust and thus more sensitive for detecting the dose–
response activity. Second, it allows one to test separately
the effect of rapamycin on the HemSCs versus cbEPCs,
which are primary ECs isolated from cord blood that serve
as prototypic young ECs. Rapamycin was administered
daily by intraperitoneal (i.p.) injection. Compared with the
vehicle-injected mice, Rapamycin caused dose-dependent
inhibition of vascularization of the Matrigel implants
(Figure 2a–c). Anti-human CD31 staining verified that
Rapamycin inhibited the de novo formation of human
CD31-positive blood vessels: CD31-positive cells were de-
tected, but without lumen formation (Figure 2d). Rapamycin
also inhibited vessel formation when HemSCs were implanted
alone (Supplementary Figure S3A, B online). Two other mTOR
inhibitors, Everolimus (Novartis, Basel, Switzerland) and
Temsirolimus (Pfizer, Groton, CT), injected systemically as
described for Rapamycin, also significantly inhibited forma-
tion of blood vessels (Figure 2e).
To test whether or not HemSCs are a target of Rapamycin,
versus the cbEPCs or a murine host cell, we pretreated
HemSCs with Rapamycin for 3 days in vitro, washed out the
drug, resuspended the Rapamycin-treated or control HemSCs
with cbEPCs in Matrigel, and injected into mice. Pretreatment
of HemSCs with Rapamycin led to 80% inhibition of blood
vessel formation (Figure 2f and g). Pretreatment of cbEPCs had
no effect (data not shown). These results demonstrate that
HemSCs are directly targeted by Rapamycin.
An anti-proliferative drug is not sufficient to inhibit
vasculogenesis in vivo
We identified Rapamycin based on its preferential inhibition
of HemSC proliferation. We then tested whether a similar
anti-proliferative effect, achieved with another drug, would
be anti-vasculogenic. To perform this, we used the anti-
proliferative drug Roscovitine, a purine analog and cyclin-
dependent kinase inhibitor (De Azevedo et al., 1997; Meijer
et al., 1997). First, we titrated the effect of Roscovitine on
HemSC proliferation in vitro. Roscovitine, at a concentration
of 1.1 mgml1 (3.125mM), led to 55% inhibition of HemSC
proliferation (Figure 3a), a similar effect to that of Rapamycin
(20 ngml1), assayed in the same experiment (not shown).
Next, we pretreated HemSCs in vitro for 3 days with either
Roscovitine or Rapamycin, washed out the drugs, and then
injected the cells with untreated cbEPC into mice. Rapamycin
inhibited microvessel density by 60%, whereas Roscovitine
did not (Figure 3b and c), suggesting that pretreatment of
HemSCs in vitro with an anti-proliferative drug was not
sufficient to reduce the vasculogenic potential.
HemSC self-renewal and multi-lineage differentiation are
disrupted by Rapamycin
Activity of mTOR has been shown to be essential for
maintaining stem cell self-renewal (Zhou et al., 2009). To
test self-renewal capacity of HemSCs, we performed a
clonogenic assay (Ingram et al., 2004). Pretreatment of
HemSCs with Rapamycin resulted in a 60% decrease in the
number of HemSC colonies formed at 9 days (Figure 4a).
Moreover, stratifying the colonies into groups with increasing
cell number demonstrated that pretreatment with Rapamycin
abolished the appearance of colonies with 4500 cells,
reduced the percentage of colonies with 100–250 or
250–500 cells per colony, and increased the percentage of
colonies with 10 or fewer cells (Figure 4b). These results
demonstrate that pretreatment of cells with Rapamycin for
4 days resulted in a diminished number of highly proliferative
clones.
Clonally derived populations of HemSCs have the ability
to differentiate into ECs and adipocytes in vitro and in vivo
(Khan et al., 2008). We assayed whether the multi-lineage
differentiation of HemSCs could be altered by Rapamycin.
Rapamycin blocked the expression of the adipogenic
markers, lipoprotein lipase CCAAT enhancer-binding pro-
tein-a (Darlington et al., 1998), and the accumulation of lipid
droplets (Oil Red-O), when HemSCs were subjected to an
adipogenic differentiation protocol (Figure 4c and d). No
effect was found on the ability of HemSCs to differentiate,
under empirically defined in vitro conditions, toward an
endothelial phenotype (data not shown). These observations
indicated that Rapamycin inhibits the adipogenic differentia-
tive activity of HemSCs.
Rapamycin leads to mesenchymal maturation and impaired
vasculogenic potential
The reduction in self-renewal capacity and inhibition of
adipogenesis suggested that Rapamycin ‘‘pushes’’ the
HemSCs to maturate past the state of multipotency. In
accordance with this hypothesis, HemSCs incubated with
Rapamycin have an elongated morphology compared with
the control cells (Supplementary Figure S2 online). Therefore,
we tested whether or not Rapamycin-treated HemSCs
differentiate toward a smooth muscle cell or pericytic
phenotype. As a positive control, we used endothelial
coculture to stimulate HemSCs toward smooth muscle cell/
pericytic differentiation. Similar to cocultures of mesenchy-
mal progenitor cells and ECs (Hirschi et al., 1998; Melero-
Martin et al., 2008), when clonal HemSCs are cocultured
with ECs, an upregulation of smooth muscle cell/pericyte
markers in the HemSCs occurs, starting on day 3 (Boscolo
et al., 2011). Incubation of HemSCs with Rapamycin for
4 days led to the upregulation of smooth muscle myosin
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heavy chain and SM22-a transcript levels (Li et al., 1996;
Figure 4e). Similarly, SM22-a and a-smooth muscle actin
were increased at the protein level (Figure 4f). Expression
levels of calponin, NG2, and PDGF-Rb were unchanged
(Supplementary Figure S4A online). To test for functional
features of smooth muscle cells, we analyzed calcium influx
in HemSCs treated with Rapamycin or DMSO for 6 days.
The results indicate that Rapamycin-treated HemSCs express
L-type voltage-gated channels (Supplementary Figure S4B
and Supplementary Movie S1 and S2 online). To verify that
this mesenchymal maturation has a negative effect on
vasculogenic capability, we plated HemSCs alone or in
coculture with cbEPCs. After 4 days, cbEPCs were separated
from the HemSCs using anti-CD31-conjugated magnetic
beads. The differentiated HemSCs were combined with fresh
cbEPCs, suspended in Matrigel, and injected into mice
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Figure 2. Rapamycin suppresses vessel formation in infantile hemangioma (IH) tumor model. (a) Dose–response to Rapamycin. Matrigel explants at day 7.
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(schematic in Figure 4g). This prior coculture step led to a
75% decrease in the microvessel density (Figure 4h and i).
These findings indicate that, independent of the means by
which mesenchymal differentiation was induced, either
Rapamycin pretreatment or endothelial coculture, the vascu-
logenic potential of HemSCs was diminished.
Rapamycin stimulates regression of preexisting vessels
formed from HemSCs
Rapamycin is known to have an anti-angiogenic effect on ECs
in pathological settings (Guba et al., 2002; Phung et al.,
2007; Geerts et al., 2008). To study this effect, we tested
Rapamycin on cbEPCs. Rapamycin suppressed growth of
cbEPCs, which was not rescued by exogenous VEGF-A or
placental growth factor-1. This observation suggests, as
expected, that proliferation and response to VEGF and
placental growth factor-1 mitogenic signals are mTOR
dependent. (Supplementary Figure S5A and B online). In
addition, Rapamycin caused a dose-dependent suppression
of endogenous placental growth factor-1 in human ECs,
including HemECs (Supplementary Figure S5C and D online).
Thus, we hypothesized that Rapamycin, able to target both
the stem cells and ECs, could cause regression of preexisting
vessels formed from HemSCs and cbEPCs. To test this, we
used contrast-enhanced micro-ultrasonic imaging to measure
blood flow in the Matrigel implants. First, we verified the
sensitivity and specificity of the micro-ultrasonic imaging in
our model (Supplementary Figure S6 online). For the
experiment, mice were injected with cells and imaged on
day 7 to record baseline blood flow in the implants. Mice
were then randomized into two groups: Rapamycin,
2mg kg1 by i.p. injection, or vehicle alone by i.p. injection.
At day 17, follow-up imaging was performed. Mice injected
with vehicle had either a stable or increased blood flow in the
implant (Figure 5a and b, red lines). Mice injected with
Rapamycin had reduced blood flow (Figure 5b, gray lines).
The average change in contrast intensity between 7 and
17 days is shown in Figure 5c (Movies of the contrast agent
(blood) flow through the implants are provided in the
Supplementary Movie S3–S6 online). In accordance with
the imaging results, Matrigel implants of Rapamycin-treated
mice were less vascularized macroscopically and by histo-
logical analysis (Figure 5d and e).
Rapamycin and corticosteroids target HemSCs by distinct
mechanisms
To investigate whether corticosteroids and Rapamycin share
common mechanisms for suppressing HemSC-mediated
vascularization, we evaluated the effect of Rapamycin on
expression of a panel of 43 proangiogenic proteins. In contrast
to corticosteroid treatment, Rapamycin did not block the
expression of VEGF-A by HemSCs at the mRNA or protein level
(Figure 6a and b). Indeed, we found no overlap between the
effects of Rapamcyin and dexamethasone on expression of the
proangiogenic cytokines. Dexamethasone suppressed VEGF-A,
IL-6, matrix metalloproteinase-1, monocyte chemoattractant
protein-1, and urokinase plasminogen activator receptor
(Greenberger et al., 2010). In contrast, Rapamycin down-
regulated angiogenin and placental growth factor-1 in
HemSCs and cbEPCs (Figure 6c, verification of the array
results in Supplementary Figure S7 online).
Because corticosteroid and Rapamycin appeared to
have nonoverlapping effects on HemSCs and ECs, we
hypothesized that the two drugs could ‘‘collaborate’’, i.e.,
vascularization would be inhibited at low doses of each drug,
comparable to either drug used alone at high dose. To test
this concept, mice were given i.p. injections of low dose
of dexamethasone (0.25mg kg1), low dose of Rapamycin
(0.25mg kg1), or the combination of both. Combining
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Rapamycin and dexamethasone enhanced their potency, as
evidenced by the inhibition of vasculogenesis that was
comparable to high dose of either drug alone (1 and
2mg kg1 of Rapamycin or dexamethasone, respectively,
Figure 6d and e). The efficacy of the two drugs at low doses
suggests that targeting the HemSCs with dexamethasone and
HemSCs and HemECs with Rapamycin may be an effective
therapy for endangering IH.
DISCUSSION
To identify novel drug candidates for the common childhood
tumor IH, we screened chemical libraries for compounds that
would inhibit the vasculogenic stem cell, HemSCs, isolated
from IH tumor tissue. We identified Rapamycin, an mTOR
inhibitor, based on its relative selectivity for HemSCs over
BM-MSCs, a normal human stem cell with a similar
phenotype. Rapamycin also suppressed self-renewal and
modified the differentiative status of the HemSCs. Finally,
Rapamycin prevented HemSCs, either alone or in combina-
tion with cbEPCs, from forming blood vessels in vivo and
increased regression of already formed vessels. Our data
suggest that the primary action of Rapamycin is to cause the
HemSCs to lose their stem cell properties; this represents an
entirely unique mechanism for blocking human postnatal
vasculogenesis. We base this on the experiments in which
pretreatment of HemSCs for defined periods of time
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diminished self-renewal in vitro and inhibited vasculogenesis
in vivo. Furthermore, inhibiting proliferation per se with
Roscovitine was not sufficient to block vasculogenesis.
An alternative mechanism to Rapamycin’s anti-vasculogenic
effect in vivo might be the inhibition of the interaction
between HemSCs and cbEPCs. Evidence for the mTOR
pathway was shown by the activation of the upstream,
positive modulator AKT in proliferating IH tumor specimens.
Finally, we show that Rapamycin exerts nonoverlapping,
inhibitory effects on HemSCs and ECs compared with
corticosteroids (see schematic in Supplementary Figure S8
online).
The role of phosphatase and tensin homolog in controlling
the homeostasis and self-renewal of stem/progenitor cells in
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multiple tissues is well established (Groszer et al., 2001;
Inoue-Narita et al., 2008; Dubrovska et al., 2009; Hill and
Wu, 2009). However, the contribution of pathways down-
stream of phosphatase and tensin homolog, and especially
the AKT/mTOR axis, is less defined. Both, overactivation and
suppression of mTOR activity has been shown to affect self-
renewal of stem cells. When human embryonic stem cells are
cultivated under self-renewal conditions, mTOR inhibition
suffices to disrupt pluripotency, and trigger mesoderm and
endoderm activities (Zhou et al., 2009). In hematopoeitic
stem cells, overactivation of the mTOR pathway by condi-
tional deletion of phosphatase and tensin homolog or
tuberous sclerosis protein 1, or by constitutive activation of
AKT (Kharas et al., 2010), led to the loss of hematopoeitic
stem cells quiescence and reduced long-term hematopoeitic
stem cells function. Rapamycin was shown to rescue
hematopoeitic stem cells function (Yilmaz et al., 2006)
(Zhang et al., 2006; Chen et al., 2008). The effects of
rapamycin treatment on IH-derived stem cells suggest that
tightly controlled mTOR activity is also essential for
postnatal, tissue-resident stem cells.
IH appears in the first few weeks of life and with higher
incidence in low birth weight preterm infants (Amir et al.,
1986). Following the proliferative phase, there is spontaneous
regression leading to a fibrofatty residuum. This unique life
cycle suggests that this tumor derives from immature progeni-
tor cells, perhaps of neural crest origin (Haggstrom et al., 2006;
Wu et al., 2008), that have not accomplished their full differen-
tiation plan. If that is the case, an intervention that will push
these cells to lose their ‘‘stemness’’, perhaps using Rapamycin
or another modulator of mTOR activity, is an appealing
strategy to prevent growth and/or induce early involution.
Taken together, our findings suggest two potential
advantages of mTOR inhibitors for the treatment of non-
responsive IH. First, our finding that corticosteroids and
Rapamycin function by distinct mechanisms to suppress the
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Figure 6. Rapamycin and corticosteroids target HemSCs by mutually exclusive mechanisms. (a) Quantitative enzyme-linked immunoassay analysis of vascular
endothelial growth factor (VEGF)-A protein in conditioned media of Rapamycin-treated infantile hemangioma (IH)-derived stem cells (HemSCs). (b) Quantitative
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vasculogenic potential of HemSCs suggests that mTOR
inhibitors can be used as ‘‘steroid sparing’’ agents, reducing
the required dose of corticosteroid. Moreover, because of the
induction of HemSCs differentiation by Rapamycin, the
treatment period might be shortened. Rapamycin has adverse
effects, but in most cases these effects are dose or concentra-
tion dependent (Sindhi et al., 2005). Second, in some patients,
the permanent fibrofatty residuum after tumor involution can
be disfiguring. We found that Rapamycin blocks HemSC
adipogenic differentiation, in accordance with previous
reports demonstrating a role for intact mTOR activity for
adipogenic differentiation (Zhang et al., 2009). It might then
be the case that treating proliferating IH with Rapamycin
would prevent this sequela and be advantageous over a
natural involution.
MATERIALS AND METHODS
IH tissue and cell culture
Specimens of IH were obtained under a protocol approved by the
Committee on Clinical Investigation, Children’s Hospital Boston; the
clinical diagnosis was confirmed in the Department of Pathology.
Informed consent was obtained for use of IH specimens, according to
the Declaration of Helsinki Principles. The derivation, sources, and
culture conditions of HemSCs and other cells used in this study have
been reported (Khan et al., 2006, 2008; Melero-Martin et al., 2007).
For coculture experiments, HemSCs and cbEPCs (104 cells per cm2)
were plated on fibronectin (1mg cm2)-coated dishes at 1:1 ratio. On
the indicated day, cells were trypsinized to prepare a single-cell
suspension. Removal of cbEPCs was performed by Dynabeads CD31
Endothelial Cells (Invitrogen, Carlsbad, CA) according to the manu-
facturer’s instructions. Differentiation assays toward endothelial cells
and adipocytes were performed as reported (Khan et al., 2008).
Animal experiments
Nude/Nude mice were purchased from the Massachusetts General
Hospital animal facility. Procedures were approved by the Animal
Care and Use Committees of the Children’s Hospital, Boston.
Anesthesia was induced with 4% isofluorane and maintained in
1–3% oxygen. Mice were anesthetized once, for up to 5min. The
one-cell and two-cell models of IH were performed as reported
(Khan et al., 2008; Greenberger et al., 2010), and microvessel
density was assessed by counting red blood cell-filled lumens
(Melero-Martin et al., 2007). Values reported for each experimental
condition correspond to the average microvessel density value
±SEM obtained from all the individual animals.
Systemic mTOR inhibitors
Rapamycin, Everolimus, and Temsirolimus were purchased from
the LC Laboratories (Woburn, MA). Drugs were dissolved in DMSO,
followed by solvent solution (5% polyethylene glycol, 0.2%
carboxymethylcellulose, and 0.25% Tween-80 in H2O). Aliquots
were maintained at 20 1C. Mice were given daily i.p. injections
containing 200ml of drug or the vehicle alone.
High-resolution contrast-enhanced ultrasonic imaging
Contrast-enhanced high-resolution ultrasonic imaging of the blood
flow in Matrigel implants was performed using a Vevo 770 System with
a 40-MHz RMV scanhead (Visual Sonics, Toronto, Ontario, Canada;
Loveless et al., 2009; Olive et al., 2009). MicroMarker non-targeting
contrast agent (Visual Sonics) was prepared according to the
manufacturer’s guidelines. For imaging, mice were anesthetized with
2% isofluorane, coupling gel was applied to cover the entire region of
interest, and 2D B-mode scout images established the central slice of
the Matrigel. The transducer was placed such that the 6-mm focal spot
converged at the center of the Matrigel. Baseline images were acquired
in Contrast Mode, and a 50-ml bolus of contrast agent suspension was
administered via tail vein catheter during acquisition of a second
contrast video. The baseline image was subtracted from the contrast
image, and the difference was displayed with a contrast setting of 90
and a threshold setting of 0. For these experiments (Figure 5), mice
were subjected to isofluorane-mediated anesthesia two times (days 7
and 15) for approximately 15mins.
Clonogenic assay
HemSCs were incubated with 20ngml1 Rapamycin or DMSO, as a
control, for 4 days. Following washout of the drug, cells were serially
diluted to eight cells per ml and plated in 384-well plates, 40ml per
well. The medium was replaced every 48h. At day 9, cells were fixed
and stained with Hoechst. Following image capture by automated
fluorescence microscopy, colony formation and the number of cells/
colony were determined by quantifying the number of wells with
Hoechst-stained nuclei and the number of Hoechst-stained nuclei/
well using MetaXpress Software (Sunnyvale, CA).
Statistical analysis
Data were analyzed by Student’s two-tailed t-test. One-way analysis
of variance was used to test for differences among multiple groups.
Differences were considered significant at Po0.05.
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